Marlissa NDC 68462-388

NDC codes

FDA NDC Directory

Product NDC (as listed)68462-388Labeler and product segments. Claims need a package NDC.

Product NDC at billing width68462-0388Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
68462-388-29	68462038829	3 BLISTER PACK in 1 CARTON (68462-388-29) / 1 KIT in 1 BLISTER PACK (68462-388-84)Marketed from Feb 29, 2012

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Marlissa
Generic name (nonproprietary): levonorgestrel and ethinyl estradiol
Dosage form: Kit
Labeler: Glenmark Pharmaceuticals Inc., USA
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 091452
Marketing start: Feb 29, 2012
Listing expires: Dec 31, 2027
Identifiers: Product ID 68462-388_c243946a-6bbb-4d5f-8081-1858771fe9deSPL ID c243946a-6bbb-4d5f-8081-1858771fe9deSPL set ID 9379d99e-c416-4dab-a817-1c110e0d4b93RxCUI 238019, 748797, 748878, 1245919UPC 0368462388297

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N468462038829 followed by a unit qualifier and the quantity

Package 68462-0388-29. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 29, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

INDICATIONS AND USAGE MARLISSA ® (levonorgestrel and ethinyl estradiol tablets) is indicated for use by females of reproductive potential to prevent pregnancy.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)